Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06118 AUSTAR
1.910
-0.080-4.02%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31
Turnover
29.06% 1.1B 55.48% 2.02B 65.14% 855.38M 23.54% 1.3B
Operating income
29.06% 1.1B 55.48% 2.02B 65.14% 855.38M 23.54% 1.3B
Cost of sales
-37.58% -868.25M -57.95% -1.54B -66.01% -631.06M -27.15% -972.45M
Operating expenses
-37.58% -868.25M -57.95% -1.54B -66.01% -631.06M -27.15% -972.45M
Gross profit
5.09% 235.74M 48.06% 479.01M 62.71% 224.32M 13.82% 323.53M
Selling expenses
0.50% -83.78M -14.52% -170.29M -36.55% -84.2M -8.47% -148.69M
Administrative expenses
-10.98% -67.81M -29.79% -128.09M -32.04% -61.1M 9.23% -98.7M
Research and development expenses
-24.66% -33.33M -35.90% -65.6M -18.60% -26.74M -13.37% -48.27M
Impairment and provision
93.58% -441K 48.57% -6.24M -209.79% -6.87M -137.60% -12.14M
-Other impairment is provision
93.58% -441K 48.57% -6.24M -209.79% -6.87M -137.60% -12.14M
Special items of operating profit
-102.17% -4.36M 1,254.77% 203.13M 2,806.13% 200.96M 61.24% 14.99M
Operating profit
-81.32% 46.01M 915.03% 311.92M 1,941.78% 246.36M 62,614.29% 30.73M
Financing income
28.59% 850K -52.78% 1.47M -65.89% 661K -45.38% 3.12M
Financing cost
-156.93% -3.75M -70.28% -4.82M -118.59% -1.46M 24.17% -2.83M
Special items of earning before tax
-19.03% 5.12M 1.75% 10.66M 29.56% 6.32M 2.80% 10.48M
Earning before tax
-80.85% 48.23M 669.42% 319.23M 1,282.84% 251.88M 239.85% 41.49M
Tax
66.79% -11.57M -371.48% -46.6M -507.66% -34.84M -108.35% -9.88M
After-tax profit from continuing operations
-83.11% 36.66M 762.60% 272.62M 1,638.88% 217.05M 323.43% 31.61M
Earning after tax
-83.11% 36.66M 762.60% 272.62M 1,638.88% 217.05M 323.43% 31.61M
Minority profit
-1,015.31% -9.18M -212.78% -4.68M -174.33% -823K -138.44% -1.5M
Profit attributable to shareholders
-78.96% 45.84M 737.76% 277.3M 1,604.51% 217.87M 309.10% 33.1M
Basic earnings per share
-79.07% 0.09 800.00% 0.54 2,050.00% 0.43 200.00% 0.06
Diluted earnings per share
-79.07% 0.09 800.00% 0.54 2,050.00% 0.43 200.00% 0.06
Currency Unit
CNYCNYCNYCNY
Accounting Standards
IASIASIASIAS
Audit Opinions
--Unqualified Opinion--Unqualified Opinion
Auditor
--PricewaterhouseCoopers--PricewaterhouseCoopers

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Aoxing Life Technology Co., Ltd. is a leading supplier of engineering solutions for high-end and integrated services and products in China, for well-known pharmaceutical companies and research institutions in China, and to provide these products and services to customers in emerging countries. On November 7, 2014, the company was successfully listed on the main board of the Stock Exchange of Hong Kong Limited (stock code: 6118). Aoxing Group was founded in 1991 and is headquartered in Beijing, China. Aoxing Group provides high-end integrated engineering solutions for customers to set up production facilities and build a clean environment, both of which are crucial to pharmaceutical production. Aoxing's solutions cover fluid and bioprocess systems, clean room and automation control and monitoring systems, powder solid systems and GMP compliance services to assist customers at critical stages of the pharmaceutical life cycle (from research, development, pilot plant, commercial production to product launch). We are also engaged in the manufacture, sales and distribution of all kinds of high-end pharmaceutical equipment and life technology consumables with the joint venture company. The value-added integration engineering solution of Aoxing Group is tailor-made for customers to create some of their production facilities. Aoxing Group assists customers in system construction and the use of hardware and software engineering and technology, including advice on system design, equipment selection, production process, production technology application and verification documentation. Our solutions include the provision of equipment, parts and advice on applied technologies that can improve the efficiency and effectiveness of our customers' production processes. Through the joint venture arrangement with STERIS and PALL, the well-known companies in the life science industry, Aoxing Group is able to integrate these products into integrated engineering solutions based on the complementary relationship with the partners of the joint venture company by making use of the pharmaceutical equipment developed and / or produced by the partners of the joint venture company and the life technology consumables developed and / or produced by the partners of the joint venture company. Provide customers with a variety of high-quality products in the product portfolio.
CEO: Guoqiang He
Market: Hong Kong motherboard
Listing Date: 11/07/2014
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist